Welcome to our dedicated page for Polypid Ltd. SEC filings (Ticker: PYPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PolyPid Ltd. (Nasdaq: PYPD) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer. PolyPid files annual reports on Form 20-F and frequent Form 6-K current reports, which provide detailed information on its clinical, regulatory, financial and corporate developments as a late-stage biopharma company.
Recent Form 6-K filings incorporate press releases on key milestones for D-PLEX100, PolyPid’s lead product candidate for the prevention of abdominal colorectal surgical site infections. These filings include reports of positive Phase 3 SHIELD II trial results, positive FDA pre-NDA meeting minutes supporting a New Drug Application submission, and the granting of Breakthrough Therapy designation. They also capture updates on the company’s regulatory strategy, such as the FDA’s agreement to a rolling NDA review.
PolyPid’s SEC reports further document manufacturing and quality milestones, including the successful completion of a Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Health under the EU-Israel ACAA framework, which the company states confirms that its facility meets standards required for commercial production in the European market. Other 6-Ks address corporate governance matters, such as changes in board leadership, executive appointments, shareholder meeting outcomes and compensation policy approvals.
Financial information is regularly furnished through interim condensed consolidated financial statements and management’s discussion and analysis, attached as exhibits to Form 6-K. Additional filings describe capital-raising arrangements, including a Sales Agreement for the issuance and sale of ordinary shares and subsequent increases to the maximum aggregate offering price.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the main points of each document, helping readers quickly understand the significance of PolyPid’s 20-F annual reports, 6-K current reports and other registered offerings without reading every line of the underlying SEC text.
PolyPid Ltd. has appointed Brooke Story as a director and chairman of its Board of Directors, effective December 11, 2025. Story, age 54, is a veteran medtech executive who has led the separation and integration management office at BD since June 2024 and previously served as Worldwide President in multiple BD business units.
Before joining BD, she held senior leadership roles at Medtronic in pelvic health and gastric therapies and has board experience at LivaNova and Sigilon Therapeutics. The Board determined she is independent under Nasdaq rules. Her compensation for Board service will be presented for approval at an upcoming shareholder meeting, and she is expected to enter into PolyPid’s standard indemnification agreement for directors and executive officers.
PolyPid Ltd. filed a Form 6-K to furnish a press release dated December 3, 2025 announcing positive U.S. FDA pre-NDA meeting minutes for its D-PLEX100 product, which support a planned New Drug Application submission. The filing states that the first three paragraphs of the press release and its forward-looking statements section are incorporated by reference into several existing PolyPid shelf and equity compensation registration statements on Forms F-3 and S-8, so that those registration documents now include this updated regulatory information.
PolyPid Ltd. (PYPD) is increasing its at-the-market share offering program to a maximum aggregate offering price of up to $15,000,000 of ordinary shares under its Form F-3 shelf. This prospectus supplement raises the prior cap of $8,250,000 and continues the sales agreement with Oppenheimer & Co. Inc. as sales agent on a best efforts basis. Oppenheimer will receive a 3.0% commission on the gross sales price per share and reimbursement of up to $40,000 of specified expenses.
The company’s ordinary shares trade on Nasdaq under the symbol PYPD; the last reported sale price was $3.68 per share on November 25, 2025. The aggregate market value of ordinary shares held by non-affiliates was $65,953,832 as of October 30, 2025, based on 17,175,477 non-affiliate shares at $3.84 per share.
PolyPid Ltd. (PYPD) reports that on November 26, 2025 it increased the maximum aggregate offering price of its ordinary shares issuable under its Sales Agreement with Oppenheimer & Co. Inc. from
The company also filed a legal opinion from Sullivan & Worcester Tel-Aviv (Har-Even & Co.) as Exhibit 5.1, addressing the legality of issuing and selling these ordinary shares under the Sales Agreement. This report is incorporated by reference into multiple existing PolyPid shelf registration statements on Form F-3 and equity compensation registration statements on Form S-8, so that future share sales under the Sales Agreement can rely on this updated disclosure.
PolyPid Ltd. submitted a Form 6-K to furnish a press release titled “PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results.” The filing notes that the press release includes recent corporate highlights, financial results for the three and nine months ended September 30, 2025, balance sheet highlights and forward-looking statements.
These specific sections of the press release, along with the attached financial statements, are incorporated by reference into multiple existing PolyPid registration statements on Forms F-3 and S-8, so they become part of those offerings from the date of this report, unless later filings supersede them.
PolyPid Ltd. furnishes a Form 6-K to report that it has issued a press release titled “PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀.” The company also states that specific portions of this press release and its forward-looking statements section are incorporated by reference into multiple existing Form F-3 and Form S-8 registration statements, so those filings now include this new information from the date of this report.
PolyPid Ltd. disclosed that Aurum Ventures M.K.I. Ltd. and Morris Kahn each report beneficial ownership of 5,001,561 ordinary shares, representing 28.1% of the class on a fully-diluted basis that counts 1,918,879 shares issuable upon exercise of currently exercisable warrants. The filing clarifies that the reported totals do not give effect to warrant "blocker" provisions that prevent exercises that would raise beneficial ownership above 9.9% at any given time, so the actual number of shares that can be owned simultaneously is lower than the aggregate reported.
The statement explains that Mr. Kahn is the ultimate sole beneficiary of Aurum and may be deemed to share beneficial ownership of the shares held by Aurum, while disclaiming day-to-day voting or investment control over Aurum-held shares.
PolyPid Ltd. submitted a Form 6-K dated August 13, 2025, furnishing its unaudited interim condensed financial statements and management's discussion and analysis for the six months ended June 30, 2025. The filing includes XBRL-formatted financial information covering interim condensed consolidated balance sheets, statements of operations, shareholders' equity, cash flows and notes, plus an embedded Cover Page Interactive Data File. The report is submitted by the Chief Executive Officer and lists related exhibit numbers for the financial statements, MD&A and XBRL tagging.
PolyPid Ltd. filed a Form S-8 to register 1,200,000 additional ordinary shares for issuance under the Amended and Restated 2012 Share Option Plan, incremental to 2,311,570 shares previously registered. The Registration Statement incorporates by reference the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024 and specified Form 6-K reports that include recent financial results for the quarters and six-month periods ended June 30, 2025.
The company's amended articles will permit exemption, indemnification and insurance of officers to the fullest extent allowed under Israeli law; PolyPid intends to obtain directors and officers liability insurance and to enter into indemnification and exemption agreements with officers, while noting the SEC view that indemnification against Securities Act liabilities is unenforceable. The filing indicates the company is an emerging growth company and a non-accelerated filer.
Rosalind Advisors, related individuals and a fund report collective beneficial ownership of 5,762,349 common shares of PolyPid Ltd., representing 9.9% of the outstanding common stock based on 15,897,201 shares outstanding per the issuer's disclosure. The reported position consists of 975,462 shares of Common Stock and 4,786,887 shares issuable upon exercise of warrants.
The filings show shared voting and dispositive power over 5,762,349 shares and no sole voting or dispositive power. The warrants include a blocker provision that prevents exercise to the extent it would increase beneficial ownership above 9.99%, and the filing states actual ownership after giving effect to those blockers is less than the amounts reported.
FAQ
What is the current stock price of Polypid Ltd. (PYPD)?
What is the market cap of Polypid Ltd. (PYPD)?
